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treatments only, in the patient care pathway. The sequence of biologics treatments 
used in both cases is: Infliximab, Adalimumab, Tocilizumab, Rituximab, Etanercept 
and salvage therapy, according to experts opinion from MINSA [2]. All patients 
received concomitant treatment with methotrexate. The characteristics included 
in model are: age, weight, initial HAQ score, severe adverse events (SAE) and clini-
cal response to short and long term treatment; randomized controlled trials were 
used as source information when local information was not available [3,4]. HAQ 
scores were used to calculate utilities, measured in QALYs [5,6,7]. Only direct costs 
were considerate from MINSA databases of 2014 [8]. A lifetime horizon time was 
used with an annual discount rate of 5%. RESULTS: Total cost and total QALY per 
patient in a lifetime period are $193,971 and 9.28 QALY for treatment sequence 
with Tofacitinib; $205,015 and 9.20 for treatment sequence with biologic therapy. 
The cost saving for treatment sequence with Tofacitinib in years one, five and ten 
were: 12%, 10%, 8% respectively. CONCLUSIONS: In case of MINSA, the sequence 
initiating with Tofacitinib is a cost-saving alternative compared with biologic 
therapy.
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OBJECTIVES: Progression of PsA can lead to irreversible damage, functional impair-
ment, and associated healthcare costs. Anti-TNF biologics have been shown to delay 
PsA progression and seem to have better efficacy compared with apremilast, a phos-
phodiesterase-4 inhibitor recently approved for PsA. The impact of using apremilast 
prior to anti-TNF has not been fully understood. This study evaluated the economic 
impacts of timely versus delayed use of anti-TNF among patients with moderately-
to-severely active PsA from a US payer perspective. METHODS: A Markov model 
was developed to evaluate the costs and outcomes of two treatment sequences over 
a one-year time horizon. PsA patients received either adalimumab (timely use of 
anti-TNF) or apremilast (delayed use) as initial treatment. Those who did not achieve 
ACR20 response in the first 12 weeks of treatment or who lost ACR20 response 
would use subsequent treatments, which included a mixture of anti-TNF biologics, 
followed by palliative care. Efficacy was based on ACR20 response, changes in the 
Health Assessment Questionnaire (HAQ), and reduction in skin lesions measured 
by the Psoriasis Area and Severity Index (PASI). Direct costs, including treatment-
related costs and other medical costs, and incremental costs per responder were 
calculated. Subgroup analyses among patients with moderate-to-severe psoriasis 
were performed. RESULTS: After one year, patients starting with adalimumab had 
higher ACR20 response rates and higher costs than apremilast (70.4% vs. 59.6%, 
$37,732 vs. $31,173). The one-year incremental cost per ACR20 responder was 
$60,766 for timely vs. delayed use of anti-TNF. Among the subgroup with psoriasis, 
starting with adalimumab lead to higher response rates in both ACR20 and PASI75 
and higher costs compared with apremilast (43.2% vs. 30.0%, $39,329 vs. $33,143). 
The incremental cost per ACR20+PASI75 responder was $46,949. CONCLUSIONS: 
Timely use of anti-TNF is a cost-effective strategy for the management of PsA due 
to improvements in joint and skin condition.
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OBJECTIVES: This study aims to perform a cost-effectiveness analysis of biologic 
alternatives for rheumatoid arthritis (RA), psoriasis (PSO) and ankylosing spon-
dylitis (AS) in Brazil, from public and private perspectives. METHODS: A deci-
sion tree model was developed for AR and PSO to evaluate the cost-effectiveness 
of biological drugs (etanercept, adalimumab, infliximab, tocilizumab, abatacept 
and rituximab). Effectiveness measures were extracted from literature and out-
comes included: ACR20 and ACR70 responses, and HQA for RA; and PASI 75 suc-
cess rate for PSO. Only costs were compared for AS because the model assumed 
the same effectiveness for drugs, according to literature review. Direct medical 
costs included biological acquisition, adverse events management and infusion 
(if applicable), presented in 2014 BRL. RESULTS: From the public perspective, in 
AR, etanercept was the most cost-effective option when compared to others drugs 
for all measures (158,731 BRL for ACR20, 282,448 BRL for ACR70 and 121,946 BRL for 
HAQ), followed by adalimumab, infliximab and tocilizumab, and rituximab. The 
same result was observed for PSO. Etanercept showed a cost-effectiveness ratio 
per PASI 75 response of 104,820 BRL versus 110,886 BRL for adalimumab. From the 
private perspective, once again etanercept was the most cost-effective option 
for all evaluated diseases. In RA, the cost-effectiveness ratios per ACR20, ACR70 
and HAQ were 193,211 BRL, 343,802 BRL, 148,435 BRL, respectively, and in PSO the 
value observed per PASI 75 response was 133,871 BRL versus 179,607 BRL for adali-
mumab and 268,504 BRL for infliximab. In AS, from both perspectives, etanercept 
represented the least costly option: 55,581 BRL versus 69,602 BRL for infliximab 
(public); 70,985 BRL versus 75,435 BRL for adalimumab and 99,883 BRL for inflixi-
mab (private). CONCLUSIONS: Etanercept showed the best cost-effectiveness ratio 
and lower costs when compared to others biological drugs in the management of 
AR, PSO and AS, from both Brazilian perspectives.
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rate-cost-age curve at 70yo prompted further consideration. Markov analysis indi-
cated the cost-effective CoP revision rate to be 12.5 revisions/100THAs at $325 cost 
difference and 9.0/100THAs at $1,003 cost difference, in a 70yo patient, indicating 
that CoP can be cost-effective. CONCLUSIONS: Shifting from MoP to CoP can be 
justified depending on the patient age, cost of the device, and actual CoP revision 
rate. All else equal, shifting all THAs in patients below age 70 to CoP and over 70 to 
MoP can be cost justified, even in the highest cost difference case.
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OBJECTIVES: Etanercept (ETA), certolizumab (CZP) and golimumab (GLM), each 
in combination with methotrexate (MTX) are the currently indicated treatment 
regimen for moderate to severe rheumatoid arthritis (RA). Recently, a novel oral 
agent, tofacitinib (CP-690550), was approved to treat RA. This study assesses the 
relative costs and effectiveness of these four disease modifying antirheumatic drugs 
(DMARDs) from a societal perspective. METHODS: We developed a Markov model 
that tracked a cohort of patients through the four disease states of RA progression, 
defined based on the patients’ disease activity score (DAS28). We estimated each 
drug’s effectiveness from published head-to-head clinical trial data. We derived 
quality of life utility scores and costs data for each disease state from the published 
literature. For each agent, we estimated the discounted costs, quality-adjusted life 
years (QALYs) and incremental cost-effectiveness ratios (ICERs). Univariate sensi-
tivity analyses were conducted to assess the impact of parameter uncertainty on 
our results. RESULTS: Relative to other drugs, and at the average US societal will-
ingness to pay (WTP) threshold of $150,000/QALY gained, ETA+MTX was the most 
cost-effective treatment regimen, with an ICER of $US 15,670/QALY gained when 
compared with CZP+MTX. The novel oral agent, CP-690550, was also relatively cost-
effective, with an ICER of $US 31,643/QALY gained relative to CZP+MTX. GLM+MTX 
was not deemed cost-effective ($239,000/QALY gained) relative to all other regimens, 
at the conventional US WTP threshold. Sensitivity analyses showed that results were 
very sensitive to the costs of each treatment. CONCLUSIONS: ETA+MTX is the most 
cost-effective treatment for moderate to severe RA in US patients. Compared to 
CZP+MTX, the novel oral agent, CP-690550, is also highly cost-effective. GLM+MTX 
is not cost-effective.
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OBJECTIVES: To compare health outcomes and costs associated with a treatment 
sequence that includes tofacitinib with another treatment sequence without tofaci-
tinib in patients with Rheumatoid Arthritis (RA) who failed to DMARDS from the 
payer’s perspective of the Ministry of public healthcare in Ecuador. METHODS: We 
compared with an Excel-based patient level simulation model, in a lifetime horizon, 
two treatment sequences, 1) treatment sequence: includes the use of tofacitinib, 
etanercept, adalimumab, tocilizumab, rituximab and salvage therapy, 2) compara-
tor sequence: includes the use of adalimumab, etanercept, inflximab, tocilizumab, 
rituximab and salvage therapy. All patients modeled received concomitant treat-
ment with methotrexate. Based on the available randomized controlled trials, HAQ 
score and clinical response to short and long term treatment data were obtained to 
calculate utilities, which were measured in QALYs. All costs information 2014 (drug 
and adverse events) were obtained from public data sources of the Ministry of Public 
Healthcare in Ecuador. RESULTS: Total costs in the lifetime horizon of treatment 
were $199,707.58 USD for the treatment sequence and $213,956.21 USD in the com-
parator sequence. Incremental costs for drug costs, administration costs, healthcare 
resources costs and other costs in the treatment sequence were -$11,881.02 USD, 
-$213.48 USD, -$460.56 USD and -1,694.60 USD respectively compared with the com-
parator sequence. Also the treatment sequence showed an incremental QALYs gain 
of 0.26 compared with the comparator sequence. CONCLUSIONS: Results suggest 
that the sequence treatment that includes the use of tofacitinib, represent a cost-
saving alternative when compared to the comparator sequence, in patients with 
Rheumatoid Arthritis (RA) who failed to DMARDS. This may represent savings for 
the Ministry of Public Healthcare in Ecuador.
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BACKGROUND: Rheumatoid Arthritis (RA) affects approximately 0.4% of the 
Latin American population over 16 years old. [1]. Many patients with rheumatoid 
arthritis (RA) do not respond adequately with disease-modifying antirheumatic 
drugs (DMARDs), being eligible for biological treatment available. OBJECTIVES: 
The objective was to evaluate the cost-effectiveness of Tofacitinib as second line 
vs continue using biological therapies in moderate RA after failure of DMARDs 
in Panama’s Ministry of Health (MINSA) in 2014. METHODS: The cost-effective-
ness model uses a patient-level simulation approach and assesses the economic 
and health benefits for the management of patients with RA who have an inad-
equate response to methotrexate. The model compares a treatment sequence 
with Tofacitinib followed by biologic treatments vs a sequence of biological 
